|
1）厚生労働省．平成23年人口動態統計月報年計（概数）の概況．2013．http://www.mhlw.go.jp/toukei/saikin/ hw/jinkou/geppo/nengai11/kekka03.html
|
|
|
|
|
2）Kuzuya M, Shimokata H, et al. Changes in serum lipid levels during a 10 year period in a large Japanese population. A cross-sectional and longitudinal study. Atherosclerosis. 2002; 163: 313-20
|
|
|
|
|
3）厚生省第4次循環器疾患基礎調査1990．同第5次調査2000．同第6次調査2010（2012）
|
|
|
|
|
|
4）Ericsson S, et al. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest. 1991; 87: 591-6
|
|
|
|
|
|
5）厚生統計協会，編．国民衛生の動向2010/2011．厚生統計協会; 2010
|
|
|
|
|
|
6）The pooling project research group: Relation of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormalities to incidence of major coronary events: final report of the pooling project. J Chron Dis. 1978; 31: 201-8
|
|
|
|
|
|
7）Benfante R, Reed D. Is elevated serum cholesterol level a risk factor for coronary heart diesease in the elderly? JAMA. 1990; 263: 393-7
|
|
|
|
|
|
8）Aronow WS, Heizig AH, Etienne F, et al. 41- month follow up of risk factors correlated with new coronary events in 708 elderly patients. J Am Geriatr Soc. 1989; 37: 501-6
|
|
|
|
|
|
9）Hayashi T, Japan CDM Group, et al. Low HDL cholesterol is associated with the risk of stroke in elderly diabetic individuals: changes in the risk for atherosclerotic diseases at various ages. Diabetes Care. 2009; 32: 1221-3
|
|
|
|
|
|
10）Maruyama T, Yamashita S, Matsuzawa Y, et al. Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia. Atherosclerosis. 2003; 166: 177-85
|
|
|
|
|
|
11）Hayashi T, Japan CDM group. Metabolic predictors of ischemic heart disease and cerebrovascular attack in elderly diabetic individuals: difference in risk by age. Cardiovasc Diabetol. 2013; 12: 1-5
|
|
|
|
|
|
12）Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet. 1995; 345: 1274-5
|
|
|
|
|
|
13）Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335: 1001-9
|
|
|
|
|
|
14）Clearfield M, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study: base line characteristics and comparison with USA population. J Cardiovasc Risk. 2000; 7: 125-32
|
|
|
|
|
|
15）Ouchi Y, et al. Serum cholesterol lowering by pravastatin reduces cardiovascular events in the elderly with hypercholesterolemia: Overall and age-related analysis of the results from the PATE study. Circulation. 1997; suppl: I-66
|
|
|
|
|
|
16）Matsuzawa Y, et al. Design and baseline characteristics of a cohort study in Japanese patients with hypercholesterolemia: The Japan Lipid Intervention Trial (J-LIT). Curr Ther Res. 2000; 61: 219-43
|
|
|
|
|
|
17）Sphered J, et al. Pravasatain in elderely individuals at risk of vascular disease (PROSPER): a randomized controlled trial Lancet. 2002; 360: 1623-30
|
|
|
|
|
|
18）Heart Protection Study Collaborative group, MRC/BHF Heart protection study of cholesterol lowering with simvastation in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002; 360: 7-22
|
|
|
|
|
|
19）Sever P, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm(ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003; 361: 1149-58
|
|
|
|
|
|
20）Nakamura H, MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006; 368(9542): 1155-63
|
|
|
|
|
|
21）Yokoyama M, Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369(9567): 1090-8
|
|
|
|
|
|
22）Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001; 104: 376-9
|
|
|
|
|
|
23）日本動脈硬化学会，編．動脈硬化性疾患予防ガイドライン2012年版．日本動脈硬化学会．（2012）Japan Atherosclerosis Society(JAS) Guidelines for Prevention of Atherosclerotic. Cardiovascular Diseases. 2012
|
|
|
|
|
|
24）Binder EF, et al. Effects of exercise training on frailty in community-dwelling older adults: Results of a randomized controlled trial. J Am Geriatr Soci. 2002; 50; 1921-28
|
|
|
|
|
|
25）Morey MC, et al. Exercise adherence and 10-year mortality in chronically ill older adults. J Am Geriatr Soci. 2002; 50; 1929-33
|
|
|
|
|
|
26）Wilund KR. The effect of endurance exercise training on plasma lipoprotein AI and lipoprotein AI:AII concentrations in sedentary adults. Metabolism. 2002; 51: 1053-60
|
|
|
|
|
|
27）Fujino Y, et al. Walking exercise and its relationship to serum lipids in Japanese. J Epidemiol. 2002; 12: 64-9
|
|
|
|
|
28）Peddi R. Dietary prescription in atherosclerosis. Clin Geriatr Med. 2002; 18: 819-26
|
|
|
|
|
|
29）Delahanty LM, et al. Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled trial. J Am Diet Assoc. 2001; 101: 1012-23
|
|
|
|
|
|
30）林 登志雄．第14回日本内科学会東海支部専門医部会教育セミナー: 生活習慣病への治療戦略「脂質異常症」．日本内科学会誌．2012; 101: 2342-9
|
|
|
|
|
|
31）Hayashi T, Nomura H, et al. Nitric oxide metabolites are associated with survival in older patients. J Am Geriatr Soc. 2007; 55: 1398-403
|
|
|
|
|
|
32）Weverling-Rijnsburger AW, et al. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997; 350: 1119-23
|
|
|
|
|
|
33）Libri V, Brown AP, et al. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One. 2012; 7: e51395
|
|
|
|
|
|
34）Derose SF, Green K, et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med. 2013; 173: 38-43
|
|
|
|
|
|
35）Farnier M, Retterstøl K, et al. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease. Diab Vasc Dis Res. 2012; 9: 205-15
|
|
|
|
|
|
36）Cushman WC, Davis BR, et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2012; 14: 20-31
|
|
|
|
|
|
37）Ray K, Wainwright WJ, et al. Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy. Heart. 2012; 98: 780-5
|
|
|
|
|
|
38）Shinozaki T, Matsuyama Y, et al. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model. Geriatr Gerontol Int. 2012; 12 Suppl 1: 88-102
|
|
|
|
|
|
39）Conde-Martel A, Formiga F, et al. Clinical characteristics and one-year survival in heart failure patients more than 85 years of age compared with younger. Eur J Intern Med. 2013; 24: 339-45
|
|
|
|
|